Verastem, Inc. is a biopharmaceutical company based in Needham Heights, MA, dedicated to developing innovative treatments for RAS pathway-driven cancers. With a focus on patients with RAS pathway mutations, which account for nearly 30% of all human cancers, Verastem Oncology is committed to exploring uncharted paths in cancer treatment to provide better options and more hope for these patients.
Driven by the goal of expanding possibilities for patients with difficult-to-treat cancers, Verastem Oncology relentlessly pursues RAS-targeted treatment combinations with avutometinib. By blocking multiple nodes in the RAS pathway, avutometinib has the potential to become a preferred backbone of therapy, offering patients more choices and the possibility of improved outcomes.
Generated from the website